Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading-
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…
Continue Reading -
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…
Continue Reading -
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…
Continue Reading -
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA
Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for…
Continue Reading -
Alex Therapeutics raises €3.5M in oversubscribed financing round
Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…
Continue Reading -
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
TargED Biopharmaceuticals raises EUR 39 Million in Series A financing
Continue Reading -
Ribbon Biolabs raises EUR 18 million in its Series A financing
Ribbon Biolabs Raises EUR 18 Million Series A Financing
Continue Reading